Apparatus and method for transdermal delivery of parathyroid hormone agents
An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.
1. A method of treating a patient having need of increased bone density comprising administering a hPTH (1-34) or salts thereof transdermally to said patient in an amount effective to increase bone density, comprising the steps of:
i) providing a device for pulsatile delivery of hPTH (1-34) comprising a microprojection member comprising a plurality of microprojections adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on at least one of said plurality of microprojections of said microprojection member, said coating being formed from a coating formulation comprising hPTH (1-34) or salts thereof, and
ii) applying said microprojection member of said device to a skin site of said patient, whereby said plurality of stratum corneum-piercing microprojections pierce the stratum corneum and deliver said hPTH (1-34) or salts thereof to said patient;
wherein said transdermal administration of said hPTH (1-34) or salts thereof to said patient is effective to achieve rapid on-set of biological action in said patient and rapid off-set after reaching Cmax, thereby effecting an increase in bone density in said patient.
2. The method of claim 1 , wherein said patient has osteoporosis.
3. The method of claim 2 , wherein said hPTH (1-34) or salts thereof is transdermally administered to said patient at a dose of approximately 10-1000 μg.
4. The method of claim 2 , wherein said hPTH (1-34) or salts thereof is transdermally administered to said patient at a dose of approximately 40 μg.
5. The method of any one of claims 1 , 2 , 3 or 4 , wherein said dose, when administered transdermally to said patient results in a plasma Cmax of at least 50 pg/ml after a single application.
6. The method of any one of claims 1 , 2 , 3 or 4 , wherein the coating allows for a pulsatile delivery profile having a baseline blood concentration in the range of 50-10000 pg/ml in a period from 1 minute to 4 hours.
7. The method of claim 6 , wherein the coating allows for a pulsatile delivery profile having a baseline blood concentration of at least 50 pg/ml in a period of 0.5 hour.
8. The method of claim 6 , wherein the coating allows for a decrease in blood serum concentration from Cmax to the baseline concentration in a period ranging from 1-8 hours after Cmax is achieved.
9. The method of claim 8 , wherein the coating allows for a decrease in blood serum concentration from Cmax to the baseline concentration in approximately four hours after Cmax is achieved.
10. The method of claim 4 , wherein said 40 μg dose of said hPTH (1-34) or salts thereof is transdermally administered in a pulsatile fashion comprising applying the microprojection member to a skin site of the patient for 30 minutes daily, and wherein the coating allows for a pulsatile delivery profile having a baseline blood concentration of at least 50 pg/ml in a period of 0.5 hour after a single application, and wherein the coating allows for a decrease in blood serum concentration from Cmax to the baseline concentration in approximately four hours after Cmax is achieved.
11. The method of any one of claims 1 , 2 , 3 or 4 , wherein said delivered hPTH (1-34) or salts thereof provides a pharmacokinetic profile similar to the pharmacokinetic profile provided by subcutaneous administration of said hPTH (1-34) or salts thereof.
12. The method of any one of claims 1 , 2 , 3 , 4 or 10 , wherein said coating formulation comprises 1.5%W/W of said hPTH (1-34) or salts thereof.
13. The method of claim 11 , wherein said coating formulation comprises 1.5%W/W of said hPTH (1-34) or salts thereof.